Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis

Abstract

This systematic review and meta-analysis suggests that NOACs may be as safe as VKAs in the setting of AF cardioversion.

Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis

“…One such retrospective cohort study by Yadlapati et al found shortterm therapy with rivaroxaban and dabigatran to be safe in AF patients undergoing cardioversion [21]. In the same vein, two studies that need mention are those by Briasoulis et al [22] and Caldeira et al [23]. The advantage of this study over the abovementioned studies is the use of the ''random effects model'', which provides a stronger methodology in the case of meta-analyses.…”

Dabigatran etexilate use in patients with non-valvular atrial fibrillation undergoing electrical cardioversion

“…Результаты, полученные в нашей работе, со-относятся с результатами других исследователей [15][16][17][18][19][20], однако во многих из них оценка конеч-ных точек проводилась на 30-90-е сутки [15,17]. В нашем же исследовании наблюдение продол-жалось до 1 года после проведения электричес-кой кардиоверсии.…”

Rivaroxabankezelés mellett kialakult bal pitvari fülcsethrombus sikeres kezelése direkt trombininhibitorral

“…Habár több klinikai vizsgálat és metaanalízis kimutatta, hogy a rivaroxabankezelés ugyanolyan hatékony és biztonságos, mint a warfarin, acenokumarol vagy dabigatran [3,4], amint azt esetünk is mutatja, közepes thromboemboliás rizikóval bíró pitvarfibrilláló betegekben rivaroxabanterápia mellett is kialakulhat intracardialis thrombus [5].…”